InnoCare Pharma Limited (HKG:9969)
Hong Kong · Delayed Price · Currency is HKD 13.65
-0.83 (-5.73%)
Sep 10, 2026, 11:59 AM HKT
InnoCare Pharma Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 29,732 | 23,687 | 12,220 | 13,112 | 23,452 | 21,094 | |
Market Cap Growth | -11.63% | 93.84% | -6.80% | -44.09% | 11.18% | 21.38% |
Enterprise Value | 23,216 | 17,849 | 6,114 | 4,689 | 14,292 | 15,136 |
Last Close Price | 14.48 | 12.30 | 6.12 | 6.89 | 13.64 | 15.30 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 24.82 | 33.13 | - | - | - | - |
PS Ratio | 9.26 | 8.96 | 11.38 | 16.11 | 33.17 | 16.48 |
PB Ratio | 3.35 | 2.75 | 1.70 | 1.66 | 2.71 | 3.04 |
P/TBV Ratio | 3.47 | 2.85 | 1.78 | 1.73 | 2.75 | 3.09 |
P/FCF Ratio | 180.30 | 1548.92 | - | - | - | - |
P/OCF Ratio | 113.36 | 253.70 | - | - | - | 102.87 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.23 | 6.75 | 5.69 | 5.76 | 20.22 | 11.82 |
EV/EBITDA Ratio | 24.88 | 30.23 | - | - | - | - |
EV/EBIT Ratio | 28.54 | 35.46 | - | - | - | - |
EV/FCF Ratio | 140.79 | 1167.14 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.29 | 0.21 | 0.23 | 0.23 | 0.20 | 0.23 |
Debt / EBITDA Ratio | 2.76 | 2.88 | - | - | - | - |
Debt / FCF Ratio | 15.63 | 117.24 | - | - | - | - |
Net Debt / Equity Ratio | -0.74 | -0.70 | -0.80 | -0.92 | -0.98 | -0.87 |
Net Debt / EBITDA Ratio | -7.27 | -10.29 | 12.00 | 10.84 | 10.21 | 29.54 |
Net Debt / FCF Ratio | -39.62 | -397.39 | 12.23 | 7.21 | 9.42 | 1821.44 |
Asset Turnover | 0.27 | 0.24 | 0.10 | 0.07 | 0.07 | 0.18 |
Inventory Turnover | 1.48 | 1.48 | 1.29 | 1.39 | 3.81 | 11.13 |
Quick Ratio | 3.87 | 5.47 | 7.01 | 4.13 | 4.43 | 19.29 |
Current Ratio | 4.22 | 5.83 | 7.45 | 4.21 | 4.48 | 19.49 |
Return on Equity (ROE) | 12.77% | 8.89% | -6.50% | -8.71% | -13.44% | -1.51% |
Return on Assets (ROA) | 4.28% | 2.79% | -3.37% | -4.15% | -5.48% | -1.91% |
Return on Invested Capital (ROIC) | 33.79% | 24.63% | -55.80% | -186.05% | -174.16% | -33.69% |
Return on Capital Employed (ROCE) | 7.80% | 4.80% | -6.20% | -8.60% | -9.40% | -2.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.57% | 3.02% | -3.84% | -5.30% | -4.27% | -0.38% |
FCF Yield | 0.55% | 0.07% | -3.86% | -7.73% | -3.82% | -0.02% |
Payout Ratio | 3.93% | 5.13% | - | - | - | - |
Buyback Yield / Dilution | -11.63% | 0.24% | 0.67% | -15.31% | -8.29% | -41.21% |